CCCC Multiplikator Forward P/S C4 Therapeutics

High drug toxicity risks and a dependence on external investments are weighing on the credit profile of C4 Therapeutics, Inc. (CCCC). On GURU.Markets, the forward P/S indicator demonstrates stable dynamics, with the metric currently standing at 11.20. Business resilience relies on the patent protection of the TORPEDO system and the diversified synthesis of molecules through partners in Massachusetts.

Advance payments from global pharma partners of C4 Therapeutics, Inc. (CCCC) directly impact the forward P/S ratio dynamics, reflecting market expectations for future revenue. This multiple compares current market capitalization with projected sales volume, allowing investors to assess the premium paid for protein degrader potential and timely recognize the risk of multiple compression during a trend correction.